LABORATORY REPORT

Name	: **JEEVITHA RANGOYI**	File. No.	: **AAL02-369592**
DOB/Gender	: **20-07-1997 (26 Yrs 5 Month 19 Days/Female)**	Referral Doctor	: **Self**
Lab No.	: **22240080172**	Referral Clinic	: **Peshawar(Irham Medical Center)**
Request Date	: **08-01-2024 13:33**	Clinic File No	: **38112**
Insurance	: **No**		

IMMUNOLOGY/SEROLOGY/INFECTIOUS DISEASES

Test Name	Result	Units	Ref. Range	Method
Hepatitis B surface Ag	0.40	Cutoff Index (COI)	Non Reactive: <0.90 Borderline: >= 0.90 to < 1.0 Reactive: >= 1.0	ECLIA
Hepatitis B "s" Ag Interpretation	Non-Reactive		Non-Reactive	

Full HepB profile is recommended in case of a Reactive result. HBs Ag Index value is an instrument dependant value and should not be used for monitoring.

For monitoring HepB levels (track treatment), a quantitative viral load by PCR is advised.

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

Please note Reference Range Reviewed w.ef 20/10/23

HIV I & II Abs + p24 Ag	0.21	Cutoff Index (COI)	Non Reactive: <1.0 Reactive: >=1.0	ECLIA
HIV Interpretation	Non-Reactive		Non-Reactive	

Kindly note above test is just a screening test.

Note: Patients at a very early stage of infection may still be non-reactive for HIV Abs or detect p24 antigen. If HIV is suspected, a control sample is recommended in 4-6 weeks.

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

Please note Reference Range Reviewed w.ef 15/10/23

Sample Type : Serum

These tests are accredited under ISO 15189:2012 unless specified by (*)
Sample processed on the same day of receipt unless specified otherwise.
Test results pertains only the sample tested and to be correlated with clinical history.
Reference range related to Age/Gender.

Dr. Solmaz Siddiqui
Laboratory Director
DHA/LS/248469

H/L Collected On : 08-01-2024 12:00:00
Authenticated On : 08-01-2024 16:30:08
Printed On : 08-01-2024 23:43:13
Received On : 08-01-2024 14:51:00
Released On : 08-01-2024 16:39:30
Reprinted On : 09-01-2024 14:50:30

Padmapriya Kumareshan
Sr. Technician
DHA/LS2992011/243822

LABORATORY REPORT

Name	: **JEEVITHA RANGOYI**	File. No.	: **AAL02-369592**
DOB/Gender	: **20-07-1997 (26 Yrs 5 Month 19 Days/Female)**	Referral Doctor	: **Self**
Lab No.	: **22240080172**	Referral Clinic	: **Peshawar(Irham Medical Center)**
Request Date	: **08-01-2024 13:33**	Clinic File No	: **38112**
Insurance	: **No**		

HORMONES/ENDOCRINE/TUMOR MARKERS

Test Name	Result	Units	Ref. Range	Method
BhCG (Beta Human Chorionic Gonadotropin)	**31629.00** H	mIU/mL	Female : Non pregnant < 5.3 Pregnant: Weeks Post LMP 3 Wk: 5.8-71.2 4 Wk: 9.5-750 5 Wk: 217-7138 6 Wk: 158-31795 7 Wk: 3697-163563 8 Wk: 32065-149571 9 Wk: 63803-151410 10 Wk: 46509-186977 12 Wk: 27832-210612 14 Wk: 13950-62530 15 Wk: 12039-70971 16 Wk: 9040-56451 17 Wk: 8175-55868 18 Wk: 8099-58176	ECLIA

Conversion Formula: (Concentration in mIU/mL) x (1) = IU/L

In non-pregnant women & men, it can also be produced by tumors of the trophoblast, germ cell tumors with trophoblastic components and some non-trophoblastic tumors.Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.Please note Reference Range Reviewed w.ef 15/10/23.

Sample Type : Serum

These tests are accredited under ISO 15189:2012 unless specified by (*)
Sample processed on the same day of receipt unless specified otherwise.
Test results pertains only the sample tested and to be correlated with clinical history.
Reference range related to Age/Gender.

Dr. Solmaz Siddiqui
Laboratory Director
DHA/LS/248469

H/L Collected On : 08-01-2024 12:00:00
Authenticated On : 08-01-2024 19:17:16
Printed On : 08-01-2024 23:43:13
Received On : 08-01-2024 14:51:00
Released On : 08-01-2024 19:31:09
Reprinted On : 09-01-2024 14:50:30

Esmeralda Obenita
Lab Incharge
DHA/LS/2992011/ 241430

LABORATORY REPORT

Name	: **JEEVITHA RANGOYI**	File. No.	: **AAL02-369592**
DOB/Gender	: **20-07-1997 (26 Yrs 5 Month 19 Days/Female)**	Referral Doctor	: **Self**
Lab No.	: **22240080172**	Referral Clinic	: **Peshawar(Irham Medical Center)**
Request Date	: **08-01-2024 13:33**	Clinic File No	: **38112**
Insurance	: **No**		

Test Name	Result	Units	Ref. Range	Method
***Pregnancy-Associated Plasma Protein-A (PAPP-A) + Down Risk Screen**	PRISCA REPORT GIVEN			
TSH (Thyroid Stimulating Hormone)	1.0400	µIU/mL	0.27-4.20 Pregnancy: 1st Trimester: 0.33 - 4.59 2nd Trimester: 0.35 - 4.10 3rd Trimester: 0.21 - 3.15	ECLIA

Conversion Formula: (Concentration in IU/ mL) x (1.0) = mIU/L. The determination of TSH serves as the initial test in thyroid diagnostics.Even very slight changes in the concentrations of the free thyroid hormones bring about much greater opposite changes in the TSH level. Accordingly, TSH is a very sensitive and specific parameter for assessing thyroid function and is particularly suitable for early detection or exclusion of disorders in the central regulating circuit between the hypothalamus, pituitary and thyroid. Please note Reference Range Reviewed w.ef 15/10/23 .

Sample Type : Serum

---------- End Of Report ----------

These tests are accredited under ISO 15189:2012 unless specified by (*)
Sample processed on the same day of receipt unless specified otherwise.
Test results pertains only the sample tested and to be correlated with clinical history.
Reference range related to Age/Gender.

Dr. Solmaz Siddiqui
Laboratory Director
DHA/LS/248469

H/L Collected On : 08-01-2024 12:00:00 Received On : 08-01-2024 19:51:00
Authenticated On : 09-01-2024 11:19:47 Released On : 09-01-2024 13:30:53
Printed On : 09-01-2024 14:50:30

Padmapriya Kumareshan
Sr. Technician
DHA/LS2992011/243822